US Penny Stocks To Watch This November 2024

As the U.S. stock market continues to rally post-election, with major indices like the S&P 500 and Nasdaq reaching record highs, investors are exploring various opportunities in different corners of the market. Penny stocks, often associated with smaller or newer companies, remain a relevant investment area despite their somewhat outdated moniker. These stocks can offer potential for growth at lower price points when backed by strong financials and fundamentals, presenting intriguing opportunities for investors looking to uncover hidden value.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.8479	$5.86M	★★★★★★
LexinFintech Holdings (NasdaqGS:LX)	$3.91	$590.24M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$161.01M	★★★★★★
RLX Technology (NYSE:RLX)	$1.65	$2.03B	★★★★★★
Better Choice (NYSEAM:BTTR)	$2.10	$4.09M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.2723	$9.41M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
PHX Minerals (NYSE:PHX)	$3.50	$131.24M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$1.10	$97.13M	★★★★★☆
So-Young International (NasdaqGM:SY)	$1.25	$86.74M	★★★★☆☆

Click here to see the full list of 748 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

ARB IOT Group (NasdaqCM:ARBB)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: ARB IOT Group Limited, with a market cap of $21.50 million, operates in Malaysia offering Internet of Things (IoT) system solutions and system integration and support services through its subsidiaries.

Operations: The company's revenue is derived entirely from its Internet of Things (IoT) segment, amounting to MYR 58.19 million.

Market Cap: $21.5M

ARB IOT Group Limited, with a market cap of $21.50 million, faces significant challenges as it reported a net loss of MYR 55 million for the year ended June 30, 2024, compared to net income in the previous year. Despite being debt-free and having short-term assets (MYR70.7M) exceeding liabilities, its earnings have declined at a very large rate over five years. Trading at nearly its fair value estimate suggests potential undervaluation; however, high volatility and lack of profitability raise concerns for investors seeking stability in penny stocks.

• Click here and access our complete financial health analysis report to understand the dynamics of ARB IOT Group.
• Examine ARB IOT Group's past performance report to understand how it has performed in prior years.

Innoviz Technologies (NasdaqCM:INVZ)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Innoviz Technologies Ltd. develops and markets automotive-grade LiDAR sensors and perception software for safe autonomous driving, with a market cap of approximately $107.24 million.

Operations: The company generates revenue from its Electronic Components & Parts segment, totaling $32.12 million.

Market Cap: $107.24M

Innoviz Technologies Ltd., with a market cap of US$107.24 million, remains unprofitable and is not expected to achieve profitability in the next three years, despite revenue generation of US$32.12 million from its Electronic Components & Parts segment. The company benefits from a debt-free balance sheet and sufficient cash runway for over a year based on current free cash flow, which exceeds both short-term (US$28.0M) and long-term liabilities (US$26.1M). Although revenue is forecasted to grow significantly at 72.58% annually, high volatility and negative return on equity (-96.49%) present challenges for investors in this penny stock category.

• Get an in-depth perspective on Innoviz Technologies' performance by reading our balance sheet health report here.
• Understand Innoviz Technologies' earnings outlook by examining our growth report.

Ovid Therapeutics (NasdaqGS:OVID)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing impactful medicines for epilepsies and seizure-related neurological disorders in the United States, with a market cap of $92.26 million.

Operations: The company generates its revenue solely from its Pharmaceuticals segment, amounting to $0.57 million.

Market Cap: $92.26M

Ovid Therapeutics, with a market cap of US$92.26 million, is pre-revenue, generating less than US$1 million annually. Despite being unprofitable and not expected to achieve profitability in the next three years, Ovid benefits from a debt-free status and ample cash runway exceeding one year based on current free cash flow. Recent leadership changes include appointing Amanda Banks as Chief Development Officer to enhance clinical development strategies. The company actively participates in healthcare conferences and explores partnerships to leverage its unique therapeutic platforms for potential growth opportunities amidst ongoing financial challenges.

• Dive into the specifics of Ovid Therapeutics here with our thorough balance sheet health report.
• Review our growth performance report to gain insights into Ovid Therapeutics' future.

Taking Advantage

• Navigate through the entire inventory of 748 US Penny Stocks here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com